FDA OKs drug to treat bleeding disorder

Apr 30, 2007

The U.S. Food and Drug Administration has approved Humate-P for the treatment of a specific bleeding disorder called von Willebrand disease.

Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) was approved for prevention of excessive bleeding during and after surgery in certain patients with mild to severe von Willebrand disease, or vWD. The disease is the most common inherited bleeding disorder, affecting about 1 percent of the U.S. population.

Humate-P is the second biological product to be approved for the management of surgery and invasive procedures in patients with vWD in whom the medication desmopressin might not work. The first biological product, Aphanate, was approved by FDA in February. However, FDA officials said Humate-P is the first product specifically for patients with severe vWD who are undergoing major surgery.

Humate-P is manufactured by CSL Behring GmbH, located in Marburg, Germany.

Copyright 2007 by United Press International

Explore further: Bangladesh jails three over drug scam that killed hundreds of children (Update)

add to favorites email to friend print save as pdf

Related Stories

Compressed diamond sheds light on mega-planets

26 minutes ago

Physicists in the United States on Wednesday reported they had compressed diamond to a density greater than that of lead, a technical feat that yields insights into the secrets of giant planets.

UP24 lifestyle bracelets take aim at waistlines

6 minutes ago

In the booming world of smart watches, pendants and bracelets that let people track sleep and steps, wearable computing pioneer Jawbone is out to win hearts through stomachs.

Recommended for you

Supermaterial gives rejected drugs a new chance

Jul 22, 2014

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments : 0